Status: Not yet recruiting
Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCL
This study is designed to evaluate the efficacy and safety of rimegepant in combination with glofitamab and CD19 CAR-T cell therapy in patients with high-risk relapsed/refractory large B-cell lymphoma. Eligible patients will be randomized to receive glofitamab plus CD19 CAR-T cell therapy with or without rimegepant. The primary endpoint is complete response rate at 6 months after CAR-T cell infusion.
Participants needed: 100
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Ruijin HospitalUpdated: May 29, 2026Locations: 1
Eligibility criteria
Able to understand and voluntarily sign the written informed consent form. [+11]
History of hypersensitivity to any study treatment or related compounds. [+14]